Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors.
Rafael Madero-MarroquinAdam S DuVallCaner SayginPeng WangSandeep GurbuxaniRichard A LarsonWendy StockAnand Ashwin PatelPublished in: British journal of haematology (2023)
Data regarding the use of FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in acute lymphoblastic leukaemia (ALL) are lacking. We identified 14 patients with FLT3- or IDH1/2-mutated ALL. Three early T-cell precursor-ALL patients received FLT3 or IDH2 inhibitors. Patient 1 maintains a complete remission (CR) with enasidenib after intolerance to chemotherapy. Patient 2 maintained a CR for 27 months after treatment with enasidenib for relapsed disease. Patient 3 was treated with venetoclax and gilteritinib at the time of relapse and maintained a CR with gilteritinib for 8 months. These cases suggest that FLT3 and IDH inhibitors could represent a viable therapeutic option for ALL patients with these mutations.
Keyphrases
- tyrosine kinase
- acute myeloid leukemia
- wild type
- epidermal growth factor receptor
- low grade
- case report
- liver failure
- newly diagnosed
- end stage renal disease
- respiratory failure
- high grade
- acute lymphoblastic leukemia
- aortic dissection
- drug induced
- squamous cell carcinoma
- diffuse large b cell lymphoma
- prognostic factors
- rheumatoid arthritis
- machine learning
- radiation therapy
- electronic health record
- hepatitis b virus
- hodgkin lymphoma
- big data
- disease activity
- locally advanced